SureTrader
Home > Boards > US Listed > Medical - Drugs >

TrovaGene, Inc. (TROV)

TROV RSS Feed
Add TROV Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 4/20/2018 10:15:46 AM - Followers: 60 - Board type: Free - Posts Today: 0

Trovagene logoTrovagene, Inc. 
11055 Flintkote Ave., Suite B
San Diego, CA 92121
USA
 
Tel: USA [+1] 858 217 4838
Fax: USA [+1] 858 217 4768 
E-mail:  service@trovagene.com
http://trovagene.com/
 
TrovaGene, Inc. is a publicly traded company molecular diagnostics company, with headquarters in San Diego, California. We are dedicated to the development and commercialization of unique, proprietary, molecular in-vitro diagnostics technologies. 
The company's founding scientists were the first to report that cell free fragments of DNA from normal cell death that circulate in the blood can cross the kidney barrier and be detected in urine. 
These cell-free nucleic fragments that pass through the kidney ("transrenal" or Tr-DNA/RNA) can be used as genetic markers of disease. The company believes that this transrenal technology will open significant new markets in the molecular diagnostics field and lead to improvements in the area of personalized medicine.

TroveGene, Inc. news

Attention: Gabriele Cerrone, Director of Trovagene
 
Gabriele Cerrone, Founder and Chairman of FermaVir Pharmaceuticals.
FermaVir Pharmaceuticals was bought out by Inhibitex (INHX) in 2007 and Gabriele Cerrone was appointed a Director of the acquiring company.
Bristol-Myers Squibb offered $2.5 Billion to acquire Inhibitex.

Bristol-Myers Squibb to Acquire Inhibitex

InhibitexReleased: 01/07/12 09:13 PM EST
Bristol-Myers Squibb Company (NYSE:BMY) and Inhibitex, Inc. (Nasdaq:INHX) announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire Inhibitex for $26.00 per share in cash pursuant to a cash tender offer and second step merger. The transaction, with an aggregate purchase price of approximately $2.5 billion, has been approved by the boards of directors of both companies. The board of directors of Inhibitex has agreed to recommend that Inhibitex's shareholders tender their shares in the tender offer. In addition, shareholders with beneficial ownership of approximately 17% of Inhibitex's common stock have entered into agreements with Bristol-Myers Squibb to support the transaction and to tender their shares in the tender offer.

Gabriele Cerrone holds an 11.4% interest in Trovagene.

Highlights:

Trovagene Closes Acquisition of CLIA Laboratory Assets
 
SAN DIEGO, Feb. 8, 2012 /PRNewswire/ -- Trovagene, Inc. (Pink Sheets: TROV.PK), a developer of trans-renal molecular diagnostics, today announced that it has closed its acquisition of MultiGEN Diagnostics, Inc.'s clinical laboratory assets.  Trovagene previously announced the execution of the Asset Acquisition Agreement on January 6, 2012.

Antonius Schuh, Ph.D. Joins TrovaGene, Inc. As Chief Executive Officer

SAN DIEGO--(BUSINESS WIRE)-- TrovaGene, Inc. (Pink Sheets: TROV.PK), a developer of trans-renal molecular diagnostics, has announced that Antonius Schuh, Ph.D. has been named Chief Executive Officer. Dr. Schuh previously served as Chairman and Chief Executive Officer of Sorrento Therapeutics, Inc. (Pink Sheets: SRNE.PK), a biotechnology company he co-founded based on a proprietary platform to generate very large fully human antibody libraries. Sorrento Therapeutics merged in 2009 with a public company supported by Phillip Frost and the Frost Group.
 
Dr. Schuh also served as the founding CEO of AviaraDx, Inc., a leading molecular diagnostic innovator in oncology. In 2008, Dr. Schuh led the sale of AviaraDx to bioMerieux, which continues to operate AviaraDx under the name bioTheranostics. Before AviaraDx, Dr. Schuh served as CEO of Arcturus Bioscience, Inc., where he led the sale of Arcturus' life science business to Molecular Devices, Inc. From 2000 to 2005, Dr. Schuh served as the President and Chief Executive Officer of Sequenom, Inc. (Nasdaq: SQNM - News). He had joined Sequenom in 1996 as Managing Dierctor of its European operations, and led during his tenure, amongst others, the commercial launch of the MassARRA® system and numerous business development and corporate acquisition transactions. Dr. Schuh holds a degree in pharmaceutics and earned his Ph.D. in medicinal chemistry from the University of Bonn, Germany.
 
"We are pleased and fortunate that Dr. Schuh joins us to lead the transition of TrovaGene from a research stage organization to a commercial enterprise," states Dr. Thomas Adams, TrovaGene's Chairman. "The company has made significant efforts to establish the utility of trans-renal nucleic acids in urine as a diagnostic sample in clinical fields as diverse as detection of minimal residual disease in oncology, infectious disease, transplant medicine and prenatal monitoring. Dr. Schuh has a proven track record of building companies and creating value for shareholders. I look forward to working with him."
 
"I have observed TrovaGene closely over the past years, as I have been intrigued by the attractive opportunities the Company's proprietary trans-renal technologies offer, and I am confident that we can introduce novel diagnostic modalities with significant clinical utility based on this platform," states Dr. Schuh.

TROV executives
TROV board


Targeted $40 Billion market space:
TROV market space



SureTrader
TROV
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SureTrader
TROV News: Current Report Filing (8-k) 04/17/2018 04:33:48 PM
TROV News: Trovagene Presents Data at AACR Meeting 2018 on Pharmacodynamic and Tumor Biomarkers During Treatment with PCM-075 and Low-Do... 04/17/2018 02:00:00 PM
TROV News: Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) 04/16/2018 05:28:50 PM
TROV News: Current Report Filing (8-k) 04/16/2018 10:16:08 AM
TROV News: Trovagene Presents Data at AACR Meeting 2018 Showing Synergy of PCM-075 in Combination with FLT3 Inhibitors in Acute Myeloid ... 04/16/2018 09:00:00 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#1092   True. They could bust over $1 for 10 Full Contact Yoga 04/20/18 10:15:46 AM
#1091   If they had great news to put out stockmule 04/20/18 09:57:47 AM
#1090   They vote in May, can occur anytime after Full Contact Yoga 04/20/18 09:32:27 AM
#1089   When is the RS happening jwest810 04/19/18 01:11:55 PM
#1088   Most definitely bad, virtually every time...but, they tend Full Contact Yoga 04/19/18 01:10:56 PM
#1087   Isn't this a very bad thing ? jwest810 04/19/18 12:54:39 PM
#1086   Yep, proxy statement on 4/16... Full Contact Yoga 04/19/18 12:52:58 PM
#1085   reverse split? jwest810 04/19/18 12:50:11 PM
#1084   RS news might be a bounce opp...running up Full Contact Yoga 04/19/18 09:24:48 AM
#1083   Yep. briphelps 04/17/18 08:42:39 AM
#1082   Nice news about the debt payoff and conference Full Contact Yoga 04/13/18 06:02:04 PM
#1081   That's good news, hopefully more enter the trial. stockmule 04/10/18 09:42:53 AM
#1080   At least high double digits. Don't have a briphelps 04/09/18 08:59:29 AM
#1079   I went back to look over the reports stockmule 04/07/18 07:35:01 PM
#1078   Briphelps. What’s your PT? cjh11 04/06/18 03:44:34 PM
#1077   I hope you are right as I am stockmule 04/06/18 09:20:47 AM
#1076   Well the tolerance of Pcm-075 of the next briphelps 04/06/18 09:15:12 AM
#1075   Interesting only two more patient results needed, out stockmule 04/06/18 09:08:12 AM
#1074   2 more patients and then we will know briphelps 04/06/18 08:53:29 AM
#1073   If we hold here it is off to stockmule 04/05/18 09:39:13 AM
#1072   Nice chart pattern since we hit the low stockmule 04/03/18 09:30:14 AM
#1071   You must be over 100k shares by now. stockmule 04/02/18 09:29:43 AM
#1070   Will never sell! Perhaps a little once it briphelps 04/01/18 01:08:52 PM
#1069   Not looking as attractive now, not sure why stockmule 03/29/18 02:01:18 PM
#1068   Ridiculous, $2 is a massive stretch Full Contact Yoga 03/27/18 08:16:11 PM
#1067   Yes $45 2-3 years! I say before! briphelps 03/27/18 08:38:50 AM
#1066   That would make the current share price north Vector93 03/22/18 04:15:12 PM
#1065   That would be nice but nothing points to stockmule 03/22/18 09:33:32 AM
#1064   Will be a $3 billion dollar company. Nothing briphelps 03/22/18 08:41:09 AM
#1063   Trovagene to Present at the 26th Annual Wall abracky 03/21/18 08:21:53 AM
#1062   Pre-market trade haven't seen that before. Nothing big stockmule 03/20/18 09:24:29 AM
#1061   It dipped a little lower than I thought stockmule 03/19/18 10:57:31 AM
#1060   Definitely something is going to happen soon and stockmule 03/14/18 06:16:36 PM
#1059   It's a POS, does it all on its Full Contact Yoga 03/14/18 04:07:09 PM
#1058   Man, there are really some forces at Play Braender 03/14/18 11:06:16 AM
#1057   Had this for awhile , think it’s the Heywood4164 03/13/18 08:23:42 PM
#1056   * * $TROV Video Chart 03-13-18 * * ClayTrader 03/13/18 04:46:54 PM
#1055   Bought some at close zino 03/13/18 04:01:07 PM
#1054   Hopefully that happens before Sept. stockmule 03/12/18 09:52:28 AM
#1053   $1.00 will be chump change if the second briphelps 03/08/18 08:03:16 AM
#1052   If we don't go below .32 maybe we stockmule 03/07/18 09:42:09 AM
#1051   * * $MSPC Video Chart 03-06-18 * * ClayTrader 03/06/18 05:06:15 PM
#1050   * * $TROV Video Chart 03-06-18 * * ClayTrader 03/06/18 05:02:37 PM
#1049   40s coming again. mojo joyo 03/06/18 02:49:05 PM
#1048   I bought in and sold at 11%. Could Hazmat927d 03/06/18 12:57:02 PM
#1047   Looks like it repeat itself over and over :-( Braender 03/06/18 11:42:07 AM
#1046   Sellers.this will be 50s and more. mojo joyo 03/06/18 10:50:57 AM
#1045   bear ambush? juancarlos 03/06/18 10:07:52 AM
#1044   48 to 55 next leg.could be a good mojo joyo 03/06/18 08:44:42 AM
#1043   40s are here mojo joyo 03/05/18 03:48:10 PM
PostSubject